BDC 2034
Alternative Names: BDC-2034Latest Information Update: 30 May 2024
At a glance
- Originator Bolt Biotherapeutics
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 10 May 2023 Bolt Biotherapeutics terminates its license with Stanford University for Boltbody™ platform (SEC File 2023- Bolt Biotherapeutics)
- 18 Aug 2022 Discontinued - Preclinical for Solid tumours in USA (Parenteral)
- 08 Apr 2022 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)